Navigation Links
New Treatment For Obstructive Sleep Apnea Now Available In Canada

SAN JOSE, Calif. and TORONTO, Nov. 19, 2012 /PRNewswire/ -- Ventus Medical is pleased to announce the introduction of its proprietary Provent® Sleep Apnea Therapy into Canada. Provent Therapy is an innovative, non-invasive treatment for obstructive sleep apnea (OSA). Provent Therapy is now available in the province of Ontario and will be available throughout Canada by June 2013. ioSleep, Inc. is the strategic distribution partner of Provent Therapy in Canada.



There is growing demand for clinically proven sleep apnea treatments and the introduction of Provent represents a scientifically validated, innovative and user-friendly approach. Provent works across mild, moderate, and severe OSA and utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep.

"According to the Public Health Agency of Canada over 1 in 4 Canadian adults are at high risk of having OSA.  OSA is suspected in patients who are loud snorers, excessively sleepy, obese and hypertensive," said Dr. John Fleetham, Professor of Medicine at the University of British Columbia. "OSA is increasingly being recognised in Canadian patients.  CPAP (continuous positive airway pressure) is the primary treatment for OSA, however not all patients can tolerate it as a long term treatment." Dr. Fleetham further comments, "I welcome new validated treatment alternatives for OSA such as Provent Sleep Apnea Therapy."

"We believe clinically-proven Provent Therapy offers a unique and convenient alternative to CPAP treatment for the large number of people in Canada currently affected by OSA," said Philip Westbrook, M.D., chief medical officer of Ventus Medical. "Provent has been used effectively in the United States since 2008 and in clinical studies, Provent Therapy improved quality of sleep while it reduced apnea (breathing disruptions), daytime sleepiness and snoring. Importantly, Provent is easy to use, portable and discreet for use at home or when travelling."

CPAP is the primary treatment of OSA and is extremely effective if worn as directed. However, up to half of all patients are not compliant with CPAP therapy due to the cumbersome nature of the treatment. Provent Therapy was developed to help patients who cannot tolerate CPAP therapy and will benefit from the small, non-invasive and effective technology, which Provent Therapy provides.

In patients with OSA the airway collapses during sleep when the muscles that hold it open relax. People with this disorder stop breathing during sleep---in some cases hundreds of times each night---usually for periods of ten seconds or longer. OSA can lead to fatigue, early morning headaches, irritability, lack of concentration, and contributes to depression, learning and memory difficulties, and sexual dysfunction. Importantly, recent studies have shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, stroke and diabetes.

"As we look at global market opportunities for Provent Therapy, Canada fits directly into our corporate strategy, which is to target markets where three factors come together: high prevalence of OSA, acceptance of innovative therapies, and importantly, a need for new therapeutic options that address low patient compliance," stated Peter Wyles, President and Chief Executive Officer of Ventus Medical. "With ioSleep and their extensive experience in sleep disorder treatment and diagnosis, we are pleased to present Provent Therapy as a new treatment to manage this troubling condition."

About Provent® Sleep Apnea Therapy

Provent is a proprietary medical device used for the treatment of OSA. The device has been shown to be clinically effective in a series of peer reviewed studies. It is an easy to use, non-invasive and disposable treatment that works across mild, moderate, and severe OSA. Provent Therapy utilizes nasal expiratory positive airway pressure (EPAP) to keep a patient's airway open during sleep and has been clinically proven in numerous studies to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow. During exhalation, the valve closes, limiting airflow through small openings, which increases expiratory pressure and keeps the airway open, preventing disruption in breathing. Provent Therapy is approved by Health Canada, is FDA cleared and has CE marking. For more information, please visit

About Ventus Medical

Ventus Medical is a privately-held medical device company dedicated to providing non-invasive medical solutions for people with sleep-disordered breathing. Based on its innovative MicroValve technology and patented designs, Ventus has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Ventus Medical devices work by creating expiratory positive airway pressure (EPAP). The company markets Provent® Therapy, a discreet, easy-to-use nasal device, for the treatment of OSA in the United States, Australia, New Zealand, Hong Kong, Singapore and Malaysia, and also markets an over-the-counter device for snoring in the United States.

About ioSleep Inc.

ioSleep is a Canadian distributor of innovative solutions for patients suffering from sleep disorders.   Dedicated to supporting both the Canadian healthcare professional and patients with clinically effective treatment options to achieve healthy sleep.  A partner that provides custom solutions that best meets the patient's needs.

SOURCE Ventus Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
Breaking Medicine Technology:
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, ... from Hillside, N.J. "Many people catch diseases simply from sitting on such dirty ... be protected from germs." , He developed the patent-pending QUDRATECS to eliminate the ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):